Scilex Holding Co (SCLXW) stock
SCLXWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SCLX
$0.04−0.00 (-1.53%)
Close on Oct 30, 2026Market cap $17.50MP/E –Yield –
Scilex revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Scilex's revenue for the twelve months ending Jun 30, 2026 was $31.61M, down 28.5% year over year. For fiscal 2025 it was $30.25M, down 46.5% from the year before. The highest annual figure on record is $56.59M in fiscal 2024.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $30.25M | -46.5% |
| FY2024 | Dec 31, 2024 | $56.59M | +21.1% |
| FY2023 | Dec 31, 2023 | $46.74M | +22.9% |
| FY2022 | Dec 31, 2022 | $38.03M | +21.4% |
| FY2021 | Dec 31, 2021 | $31.32M | +32.9% |
| FY2020 | Dec 31, 2020 | $23.56M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $7.64M | -22.8% |
| Q1 FY2026 | Mar 31, 2026 | $8.61M | +72.1% |
| Q4 FY2025 | Dec 31, 2025 | $4.79M | -67.8% |
| Q3 FY2025 | Sep 30, 2025 | $10.56M | -26.8% |
| Q2 FY2025 | Jun 30, 2025 | $9.90M | -39.5% |
| Q1 FY2025 | Mar 31, 2025 | $5.00M | -54.0% |
| Q4 FY2024 | Dec 31, 2024 | $14.90M | +10.7% |
| Q3 FY2024 | Sep 30, 2024 | $14.44M | +42.7% |
| Q2 FY2024 | Jun 30, 2024 | $16.37M | +30.1% |
| Q1 FY2024 | Mar 31, 2024 | $10.88M | +2.9% |
| Q4 FY2023 | Dec 31, 2023 | $13.46M | +12.9% |
| Q3 FY2023 | Sep 30, 2023 | $10.12M | -11.1% |
| Q2 FY2023 | Jun 30, 2023 | $12.58M | +58.7% |
| Q1 FY2023 | Mar 31, 2023 | $10.58M | +55.3% |
| Q4 FY2022 | Dec 31, 2022 | $11.92M | – |
| Q3 FY2022 | Sep 30, 2022 | $11.38M | – |
| Q2 FY2022 | Jun 30, 2022 | $7.93M | – |
| Q1 FY2022 | Mar 31, 2022 | $6.81M | – |